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Abstract
The objective of this study was to investigate the interaction
between levels of BAFF (B-cell activation factor of the tumour
necrosis factor [TNF] family) and APRIL (a proliferation-inducing
ligand) and B-cell frequencies in patients with systemic lupus
erythematosus (SLE) and rheumatoid arthritis (RA) treated with
the B-cell-depleting agent rituximab. Ten patients with SLE were
treated with rituximab in combination with cyclophosphamide
and corticosteroids. They were followed longitudinally up to 6
months after B-cell repopulation. Nine patients with RA,
resistant or intolerant to anti-TNF therapy, treated with rituximab
plus methotrexate were investigated up to 6 months after
treatment. The B-cell frequency was determined by flow
cytometry, and serum levels of BAFF and APRIL were measured
by enzyme-linked immunosorbent assays. BAFF levels rose
significantly during B-cell depletion in both patient groups, and
in patients with SLE the BAFF levels declined close to pre-
treatment levels upon B-cell repopulation. Patients with SLE had
normal levels of APRIL at baseline, and during depletion there
was a significant decrease. In contrast, patients with RA had
APRIL levels 10-fold higher than normal, which did not change
during depletion. At baseline, correlations between levels of B
cells and APRIL, and DAS28 (disease activity score using 28
joint counts) and BAFF were observed in patients with RA. In
summary, increased BAFF levels were observed during absence
of circulating B cells in our SLE and RA patient cohorts. In spite
of the limited number of patients, our data suggest that BAFF
and APRIL are differentially regulated in different autoimmune
diseases and, in addition, differently affected by rituximab
treatment.
Introduction
Systemic lupus erythematosus (SLE) and rheumatoid arthritis
(RA) are chronic inflammatory rheumatic diseases, in which
autoantibodies are part of the early disease manifestations. A
pathogenic involvement of B cells is well documented in SLE
and implicated in RA. Rituximab is a chimeric monoclonal anti-
body that depletes B cells by targeting CD20, a surface mol-
ecule expressed exclusively on B cells. After rituximab infusion,
circulating B cells are rapidly depleted and remain absent for
months. Although originally developed to treat B-cell lympho-
mas, it has also been used successfully in various autoimmune
diseases, including SLE and RA (reviewed by Eisenberg [1]).
Recently, two closely related cytokines that belong to the
tumour necrosis factor (TNF) family and that are important for
B-cell development and function were described: BAFF (B-
cell activation factor of the TNF family, BlyS, THANK, TALL-1,
TNFSF13b, zTNF-4) and APRIL (a proliferation-inducing lig-
and, TNFSF13a) [2]. They share two receptors, BCMA (B-cell
maturation antigen) and TACI (transmembrane activator and
APRIL = a proliferation-inducing ligand; BAFF = B-cell activation factor of the tumour necrosis factor family; BAFF-R = B-cell activation factor of the 
tumour necrosis factor family receptor; BCMA = B-cell maturation antigen; DAS28 = disease activity score using 28 joint counts; ELISA = enzyme-
linked immunosorbent assay; IFN = interferon; Ig = immunoglobulin; IL = interleukin; RA = rheumatoid arthritis; rs = Spearman r; SLAM = systemic 
lupus activity measure; SLE = systemic lupus erythematosus; TACI = transmembrane activator and CAML (calcium-modulating cyclophilin ligand) 
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CAML [calcium-modulating cyclophilin ligand] interactor),
which are found mainly on B cells and plasma cells (reviewed
by Ng and colleagues [3] and Schneider [4]). The third recep-
tor specific for BAFF, BAFF-R (BAFF receptor, BR3), is found
mainly on B cells, plasma cells, but also on some subsets of T
cells [3,4]. So far, APRIL has no specific receptor of its own,
but it has been shown to bind proteoglycans [5]. With the
above receptors expressed mainly on B cells, these cells are
the major consumers of these cytokines.
BAFF is produced constitutively by stromal cells within lym-
phoid organs [6] and is inducible by cells of myeloid origin
(monocytes, macrophages, neutrophils, and dendritic cells)
and also by osteoclasts (reviewed by Ng and colleagues [3]
and Dillon and colleagues [7]). APRIL is produced mainly by
the same cells as BAFF [3,7]. It was recently demonstrated
that some B cells also produce BAFF; examples are tonsillar
germinal centre B cells, Epstein-Barr virus-infected B cells, in
vitro anti-immunoglobulin (Ig)- and CD40L-activated B cells,
and non-Hodgkin lymphoma B cells. [8-11].
Overexpression of BAFF in mice leads to autoimmunity with
SLE-like symptoms, while mature B cells are lacking in BAFF-
deficient mice [2]. In contrast, mice deficient for APRIL have
normal peripheral B-cell populations but increased numbers of
effector/memory T cells. Mice overexpressing APRIL have an
increased frequency of B cells and an increased level of serum
IgM [7].
Abnormal levels of both BAFF and APRIL have been observed
in patients with SLE, RA, and Sjögren's syndrome [12-16].
With regard to the strong impact of BAFF and APRIL on B-cell
development/function and the deviated levels in SLE and RA,
it was of interest to study the effects of rituximab-induced B-
cell depletion on these cytokines. We chose to follow changes
in BAFF and APRIL serum levels after rituximab therapy in 10
patients with SLE and nine patients with RA. In all patients,
BAFF levels increased significantly during B-cell depletion. In
contrast, APRIL levels in SLE started out normal and
decreased, whereas in RA the levels were high and remained
unaffected by rituximab. These data, based on a limited
number of patients, suggest that BAFF and APRIL are differ-
entially regulated in different autoimmune diseases and, in
addition, differently affected by rituximab-induced B-cell
depletion.
Materials and methods
Patients and controls
Ten patients with refractory and active SLE (as defined by the
American College of Rheumatology criteria) [17] received four
weekly infusions (375 mg/m2) of rituximab (Mabthera, Rituxan;
Roche, Basel, Switzerland). Cyclophosphamide (0.5 g/m2)
was included at the first and fourth occasions, and corticoster-
oids were given through the whole treatment. After the fourth
infusion, no therapy other than corticosteroids was given until
repopulation occurred. All patients showed a clinical response
measured as SLAM (systemic lupus activity measure) score
(Table 1 and [18]) or in histopathological analysis of kidney
biopsies (I. Gunnarsson, personal communication).
Nine patients with active RA, non-responders (did not reach
ACR20 [American College of Rheumatology 20% response
criteria]) or intolerant to anti-TNF-α therapy (adverse reac-
tions), received two rituximab infusions (1,000 mg/infusion)
with an interval of 14 days in combination with oral methotrex-
ate (10 to 20 mg/week). Corticosteroids were given through-
out the treatment. The clinical response at B-cell depletion and
6 months is presented in Table 2.
All patients were recruited from the Rheumatology Clinic at the
Karolinska University Hospital, Stockholm, Sweden. Thirteen
non-treated healthy subjects, median age 60 years (range 20
to 85 years), were used as controls. This study was performed
after human ethics approval, and informed consent was
obtained from all contributing individuals.
B-cell-related time points for analysis
With the known variability in time to B-cell return after rituximab
treatment and with the aim of correlating changes of BAFF and
APRIL levels to the absence/presence of circulating B cells,
we chose to study serum levels of BAFF and APRIL in the
patients with SLE at B-cell-related time points: that is, (a) at
baseline (before treatment), (b) at depletion (B cells less than
0.5% of lymphocytes and less than 0.01 × 109 per litre of
blood), (c) at repopulation (when B cells constitute a signifi-
cant number of lymphocytes [greater than 1.0%]), and (d) at
recovery (the next following sample [2 to 6 months] after
repopulation). Three patients were followed for 12 months
after repopulation and two patients for 24 months after repop-
ulation. Patients with RA were analysed (a) at baseline (before
treatment), (b) at depletion (B cells less than 0.5% of lym-
phocytes and less than 0.01 × 109 per litre of blood), and (c)
6 months after baseline.
Serum levels of BAFF and APRIL
Serum levels of BAFF were measured by an enzyme-linked
immunosorbent assay (ELISA) kit from R&D Systems, Inc.
(Minneapolis, MN, USA), and serum levels of APRIL were
measured by an ELISA kit from Bender MedSystems GmbH
(Vienna, Austria). No confounding effect of rheumatoid factor
on APRIL levels was observed. Samples were analysed in
duplicates, and the mean coefficient of variation was 8.3% in
the BAFF assay and 15.4% in the APRIL assay. Both kits were
used according to the manufacturers' instructions.
Levels of B cells
The clinical immunology and clinical pathology laboratories at
Karolinska University Hospital analysed the B-cell frequencies
and numbers (CD19+) according to clinical routine by flow
cytometry.Available online http://arthritis-research.com/content/8/6/R167
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Statistical analysis
Statistical analysis was performed using GraphPad Prism
3.03 (GraphPad Software, Inc., San Diego, CA, USA) and
Statistica 7.1 (StatSoft, Inc., Tulsa, OK, USA). For comparison
of paired samples before and after treatment, Wilcoxon
matched pairs test was used, Mann-Whitney analysis was per-
formed for differences between groups, and Spearman's rank
order test was used for correlations of parameters.
Results
BAFF levels increased after B-cell depletion in patients 
with both SLE and RA
Serum levels of BAFF were followed in 10 patients with SLE
before and after rituximab treatment. Upon B-cell depletion,
BAFF levels increased significantly relative to baseline (that is,
prior to treatment): baseline 2.82 ng/ml (range 0.71 to 5.94
ng/ml) and depletion 5.45 ng/ml (range 0.80 to 7.72 ng/ml, p
Table 1
Disease activity, B-cell status, BAFF, and APRIL at all time points in patients with SLE
ID S4 S5 S7 S11 S13 S14 S16 S17 S19 S20
Age (in years)/gender 27/F 56/F 33/F 50/F 33/F 33/F 19/F 35/F 56/F 51/F
SLAM Baseline 25 14 7 12 4 22 9 14 12 8
Depletion 11 13 6 10 n.d. 16 11 12 9 n.d.
6 months post-treatment 8 11 4641 3 n . d . 9n . d . 1
Percentage of CD19+ B  c e l l s B a s e l i n e 56221 5 1 8 6881
Depletion bdl bdl bdl bdl n.d. bdl bdl bdl bdl bdl
R e p o p u l a t i o n 54 81 1 34842
R e c o v e r y 26 91 8 1 0 n . d . 81 2 5
12 months after repopulation 8 11 11
24 months after repopulation 13 18
CD19+ B cells × 109 p e r  l i t r e B a s e l i n e 0 . 0 40 . 0 40 . 0 10 . 0 10 . 2 30 . 0 50 . 0 30 . 0 50 . 0 50 . 0 1
Depletion bdl bdl bdl bdl bdl bdl bdl bdl bdl bdl
Repopulation 0.05 0.04 0.03 0.22 0.01 n.d. 0.08 0.03 0.02
Recovery 0.01 0.04 0.04 0.36 0.03 n.d. 0.11 0.07 0.04
12 months after repopulation 0.10 0.14 0.08
24 months after repopulation 0.17 0.40
B A F F  ( n g / m l ) B a s e l i n e 0 . 7 11 . 8 33 . 7 25 . 9 43 . 2 93 . 0 51 . 9 63 . 2 81 . 3 32 . 5 9
Depletion 0.80 5.50 7.72 7.20 n.d. 5.40 n.d. 6.97 2.45 5.21
Repopulation 1.79 n.d. 16.3 4.70 4.08 n.d. 4.54 2.00 4.94
Recovery 3.98 4.47 14.1 3.03 3.30 1.46 2.60 1.41 3.95
12 months after repopulation 3.51 1.36 2.85
24 months after repopulation 2.83 2.53
APRIL (ng/ml) Baseline 7.86 17.8 6.40 15.1 0.92 17.8 0 182 0.34 10.6
Depletion 1.56 3.02 3.15 3.53 n.d. 10.8 n.d. 176 0.99 5.75
Repopulation 8.62 n.d. 1.56 9.20 5.06 n.d. 93.9 1.24 6.65
Recovery 11.9 2.45 1.24 22.7 4.49 0 65.2 2.21 5.50
12 months after repopulation 1.62 40.9 6.46
24 months after repopulation 1.24 23.8
APRIL = a proliferation-inducing ligand; BAFF = B-cell activation factor of the tumour necrosis factor family; bdl, below detection limit; F, female; 
n.d., not determined; SLAM, systemic lupus activity measure; SLE, systemic lupus erythematosus.Arthritis Research & Therapy    Vol 8 No 6    Vallerskog et al.
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< 0.01) (Figure 1a). In one patient, the BAFF level did not
increase until time of repopulation (Figure 1a, Table 1).
When B cells repopulated the circulation (that is, consisted of
more than 1% of total lymphocytes), BAFF levels decreased
(median 4.54 ng/ml, range 1.79 to 16.3 ng/ml), and at time of
recovery, 2 to 6 months after repopulation, the levels
decreased further toward pre-treatment values (median 3.30
ng/ml, range 1.41 to 14.1 ng/ml). Twelve months after repop-
ulation, BAFF levels had a median of 2.85 ng/ml (range 1.36
to 3.51 ng/ml, n = 3) and remained similar 24 months post-
repopulation (2.53 and 2.83 ng/ml, n = 2) (Table 1).
These results were comparable with the nine rituximab-treated
patients with RA although a different B-cell depletion protocol
was used. Here, at depletion, a threefold increase compared
with baseline in BAFF was observed: baseline 1.31 ng/ml
(range 0.75 to 3.42 ng/ml) and depletion 4.17 ng/ml (range
2.62 to 7.9 ng/ml, p < 0.01) (Figure 1c, Table 2). Only in one
patient did the levels of BAFF remain unchanged (R11). In the
five patients who were followed for 6 months, the levels
remained elevated (median 4.46 ng/ml, range 1.59 to 6.33 ng/
ml) (Table 2). At this time point, the B cells had not yet repop-
ulated. Figure 2a and 2b (top row) illustrate levels of BAFF and
B-cell frequency in two SLE and two RA patients at the B-cell-
related time points.
The healthy subjects had a median of 0.81 ng/ml of BAFF
(range 0.56 to 1.67 ng/ml, indicated as grey bars on y-axis in
the diagrams in Figure 1). Before treatment, there was a signif-
icant difference (p < 0.001) in BAFF levels between patients
with SLE and healthy controls, whereas there was no signifi-
cant difference between the patients with RA and healthy con-
trols.
APRIL levels decreased during B-cell depletion in 
patients with SLE
In contrast to the observed increase in BAFF levels, APRIL
decreased significantly from a median of 9.25 ng/ml (range 0
to 182.3 ng/ml) to 3.34 ng/ml (range 0.99 to 175.7 ng/ml)
during B-cell depletion in our SLE cohort (p < 0.05) (Figure
1b, Table 1). This occurred in all but one patient (S19). At
repopulation and recovery, the levels were still below baseline
levels (median 6.65 and 4.49 ng/ml, respectively). Levels of
APRIL remained low 12 and 24 months after repopulation
(median 6.46 ng/ml, range 0.86 to 40.9 ng/ml [n = 3] and
1.24 and 23.8 ng/ml [n = 2], respectively) (Table 1). In healthy
subjects, the range was 0 to 46.6 ng/ml (median 4.68 ng/ml)
and is indicated as grey bars on y-axis in the diagrams in Figure
1.
In contrast to the normal levels of APRIL in the patients with
SLE, the patients with RA had significantly higher levels of
Table 2
Disease activity, B-cell status, BAFF, and APRIL at all time points in patients with RA
ID R1 R3 R7 R9 R11 R14 R15 R16 R17
Age (in years)/gender 38/F 73/M 60/F 64/F 60/F 66/F 63/F 60/F 58/M
D A S 2 8 B a s e l i n e 6 . 7 88 . 1 4 5 . 6 95 . 8 17 . 6 96 . 4 87 . 4 n . d . 5 . 5 2
Depletion 4.42 5.43 n.d. 3.84 n.d. n.d. 1.97 1.93 n.d.
6 months post-treatment 3.14 4.41 2.89 2.51 4.51 3.01
Percentage of CD19+ B cells Baseline 1 4 4 8 7.6 1.7 6 9.6 7
Depletion bdl bdl n.d. bdl bdl bdl bdl bdl bdl
6 months post-treatment 0.5 bdl bdl bdl 1
CD19+ B cells × 109 p e r  l i t r e B a s e l i n e 0 . 0 20 . 0 5 0 . 0 40 . 1 40 . 1 90 . 0 10 . 0 60 . 1 80 . 0 8
Depletion bdl bdl n.d bdl bdl bdl bdl bdl bdl
6 months post-treatment bdl bdl bdl bdl 0.01 bdl
B A F F  ( n g / m l ) B a s e l i n e 1 . 0 13 . 4 2 0 . 9 20 . 7 51 . 3 31 . 3 11 . 9 02 . 3 01 . 0 8
Depletion 4.27 7.90 n.d. 2.62 n.d. 4.06 3.12 3.51 4.41
6 months post-treatment 5.88 6.34 4.46 2.83 1.59
APRIL (ng/ml) Baseline 409 77.8 189 5.04 96.7 124 179 23.7 39.5
Depletion 412 54.3 n.d. 2.53 n.d. 112 160 38.2 61.7
6 months post-treatment 419 32.0 113 1.12 97.1
APRIL = a proliferation-inducing ligand; BAFF = B-cell activation factor of the tumour necrosis factor family; bdl = below detection limit; DAS28, 
disease activity score using 28 joint counts; F, female; M, male; n.d., not determined; RA, rheumatoid arthritis.Available online http://arthritis-research.com/content/8/6/R167
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APRIL at baseline (p < 0.05) (median 96.7 ng/ml, range 5.04
to 409 ng/ml) (Figure 1d, Table 2), and also had higher levels
than the healthy controls (p < 0.001). Upon B-cell depletion,
no significant changes were observed (median 86.7 ng/ml,
range 2.53 to 413 ng/ml), and in the five patients followed for
6 months post-treatment, the median was 97.1 ng/ml (range
1.12 to 419 ng/ml) (Table 2). On an individual level, five of nine
patients downregulated APRIL levels during depletion, two
Figure 1
Serum cytokine levels at B-cell-related time points Serum cytokine levels at B-cell-related time points. Left panels: levels of (a) BAFF and (b) APRIL in patients with systemic lupus erythematosus 
(SLE) at baseline (n = 10), depletion (n = 8), repopulation (n = 7), and recovery (n = 9). A significant increase compared with baseline was 
observed in BAFF at depletion (p < 0.01) and at repopulation (p < 0.05). In APRIL, a significant decrease (p < 0.05) occurred at depletion com-
pared with baseline. Left panels: levels of (c) BAFF and (d) APRIL in patients with rheumatoid arthritis (RA) at baseline (n = 9), depletion (n = 8), 
and 6 months after infusion (n = 5). There was a significant increase (p < 0.01) in BAFF levels at depletion compared with baseline. Middle panels: 
longitudinal levels of BAFF and APRIL in patients with (a, b) SLE and (c, d) RA; each line corresponds to a different patient. The y-axis has the same 
scale as the axis in the box-plots. Right panels: relative changes compared with baseline of BAFF and APRIL in patients with (a, b) SLE and (c, d) 
RA. Relative change = sample X/baseline sample. The grey bar on the y-axis illustrates the level in healthy controls (*p < 0.05, **p < 0.01). APRIL, a 
proliferation-inducing ligand; BAFF, B-cell activation factor of the tumour necrosis factor family.Arthritis Research & Therapy    Vol 8 No 6    Vallerskog et al.
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upregulated, and two had unchanged levels of APRIL at deple-
tion. Analysis of APRIL levels in 13 healthy subjects demon-
strated that the difference between patients with SLE and RA
was not due to differences in age distribution (data not
shown).
After B-cell depletion, the levels of APRIL paralleled the fre-
quency of B cells in most patients with SLE (Figure 2a, bottom
row). In contrast, different patterns were observed in patients
with RA as illustrated in Figure 2b (bottom row). There was a
significant negative correlation between the B-cell frequency
and APRIL serum levels (Spearman r [rs] = -0.80, p < 0.05) in
the patients with RA before treatment (Figure 3a). This was
also found for the number of B cells and serum levels of APRIL
(rs = -0.67, p < 0.05) in the same patients (Figure 3b). We also
observed a positive correlation between disease activity score
using 28 joint counts (DAS28) in patients with RA and circu-
lating levels of BAFF (rs = 0.76, p < 0.05) (Figure 3c). This cor-
relation was valid for the baseline samples only, but at no other
time points. No correlations between measured parameters
were found in the patients with SLE.
Discussion
This is the first study to demonstrate both an increase in BAFF
levels in patients with SLE and a differential effect on APRIL in
patients with SLE and RA treated with the B-cell-depleting
agent rituximab. BAFF levels increased significantly after B-
cell depletion and decreased upon repopulation in our SLE
cohort. Similar changes have been demonstrated in patients
with RA and primary Sjögren's syndrome treated with different
rituximab protocols, suggesting that this pattern is a conse-
quence of the B-cell depletion per se (Figure 1a,c; data by
Cambridge and colleagues [19] and Seror and colleagues
[20]).
BAFF and APRIL before treatment
In RA, the levels of BAFF were close to normal before treat-
ment (at baseline) in the majority of patients (n = 9), and three
patients (33%) had higher-than-normal levels. This is in
accordance with previously published studies by Cheema and
colleagues [21], who describe increased levels of BAFF in
22% of patients (15 of 67) with RA, and Groom and col-
leagues [22], who report increased BAFF levels in 19% of
their RA patient cohort. In most patients with SLE, the levels of
BAFF were above normal before treatment, which also agrees
with data from earlier studies [12-16]. These increased BAFF
levels in SLE patients could be one contributing factor in the
observed increased frequency of plasmablasts, as these cells
express both BCMA and BAFF-R [23-25]. Also, the increased
levels of BAFF could contribute to survival of autoreactive B
cells that would otherwise succumb to negative selection. This
has also been suggested by Pers and colleagues [15] and
Figure 2
Relation between cytokine levels and B-cell frequency Relation between cytokine levels and B-cell frequency. (a) Two patients with systemic lupus erythematosus (SLE) (S5 and S14) representing the 
relation of B-cell frequency (left y-axis in diagrams) and cytokine levels (right y-axis) of BAFF (top row) and APRIL (bottom row) at B-cell-related time 
points. Dashed line depicts the cytokine level, and the unbroken line depicts the B-cell frequency. (b) Two patients with rheumatoid arthritis (RA) 
(R17 and R3) representing the relation of B-cell frequency (left y-axis) and levels of cytokines (right y-axis) BAFF (top row) and APRIL (bottom row) 
at baseline, depletion, and 6 months after treatment. APRIL, a proliferation-inducing ligand; BAFF, B-cell activation factor of the tumour necrosis fac-
tor family.Available online http://arthritis-research.com/content/8/6/R167
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Kalled [26]. Levels of APRIL were within the normal range in
our SLE cohort. In the literature, there are contrasting reports
regarding APRIL levels in SLE. Stohl and colleagues [27]
describe normal levels in a majority of patients (n  = 68),
whereas Koyama and colleagues [28] report increased serum
levels in their patients (n = 48). In our small patient cohort, we
did not find any correlations between measured parameters
(SLAM, frequency of B cells, number of B cells, BAFF, and
APRIL) (Table 1) at any time point.
In contrast to the SLE patients, the patients with RA had on
average 10-fold higher levels of APRIL in serum. However, in
three of nine patients, we measured normal levels. There are a
few publications regarding APRIL in patients with RA. Koyama
and colleagues [28] report normal serum levels in a cohort of
21, three of whom were above normal. Tan and colleagues
[29] show higher APRIL levels in synovial fluid compared with
serum. In addition, Seyler and colleagues [13] studied mRNA
levels of APRIL in synovial biopsies, in which the samples were
classified as germinal centre synovitis, aggregate synovitis, or
diffuse synovitis, ranking inflammatory activity from severe to
mild, respectively. The tissue expression of APRIL mRNA was
the highest in germinal centre-positive synovitis and the lowest
in diffuse synovitis. The authors suggest that APRIL mRNA lev-
els correlate with the variability of tissue B-cell function.
At this point, we can only speculate why we see different levels
of BAFF and APRIL in our two patient cohorts. The high circu-
lating levels of APRIL in RA are striking even though our
patient cohort is small. From the data by Seyler and colleagues
[13] as described above, we could speculate that all RA
patients included in our study have germinal centre synovitis.
Another hypothesis is that different cytokine profiles induce
different amounts of BAFF and APRIL. Patients with SLE have
increased levels of interferon (IFN)-α and IL-10 [30,31], and
these cytokines induce production of BAFF while APRIL
expression is upregulated by IFN-γ and IFN-α (reviewed by Ng
and colleagues [3]). BAFF and APRIL are also probably pro-
duced by different cell subsets in RA and SLE. Osteoclasts
derived from the inflamed RA joint have been shown to be
good producers of APRIL [32]. It has been shown that synovial
fluid from patients with active RA contains high levels of BAFF
and APRIL, probably locally produced in the joint by neu-
trophils, dendritic cells, and macrophages [13,29]. Addition-
ally, fibroblast-like synoviocytes secrete BAFF after stimulation
with IFN-γ and TNF-α, which are known to be effector
cytokines in the RA joint [33]. Thus, different cytokine milieus
and different cells producing BAFF and APRIL in the two dis-
eases could contribute to this divergent finding. Previous treat-
ment regimens could also provide clues to the different levels
of BAFF and APRIL in patients with SLE and RA. In this con-
text, already at baseline, our cohort of patients with SLE were
treated with cyclophosphamide and our patients with RA with
methotrexate and/or anti-TNF-α therapy.
Interestingly, despite our small RA patient group, before treat-
ment we found several statistical correlations, which however
need to be confirmed in larger patient cohorts. Also, the bio-
Figure 3
Correlations of BAFF (B-cell activation factor of the tumour necrosis factor family) and APRIL (a proliferation-inducing ligand) Correlations of BAFF (B-cell activation factor of the tumour necrosis factor family) and APRIL (a proliferation-inducing ligand). (a) Negative correla-
tion of the B-cell frequency and APRIL levels in serum at baseline in patients with rheumatoid arthritis (RA) (Spearman r [rs] = -0.8, p < 0.05). (b) 
There was also a correlation between the number of B cells and levels of APRIL in serum at baseline in the patients with RA (rs = -0.67, p < 0.05). 
(c) Moreover, a correlation between the disease activity score using 28 joint counts (DAS28) and circulating levels of BAFF at baseline in patients 
with RA was found (rs = 0.76, p < 0.05). Each dot represents a different patient, and the line illustrates the slope of r.Arthritis Research & Therapy    Vol 8 No 6    Vallerskog et al.
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logical significance of these correlations, a positive correlation
between DAS28 and serum levels of BAFF and negative cor-
relations between levels of APRIL and B-cell frequency and
number, are now subject to further investigations.
Effects on BAFF and APRIL after B-cell depletion
During B-cell depletion upon rituximab treatment, levels of
BAFF increased in both patients with SLE and RA. That this
increase occurred despite different treatment protocols sug-
gests that this change is likely to be a consequence of the B-
cell depletion per se. Similar results have been presented in
two other studies of rituximab-induced B-cell depletion in
rheumatic patients, one by Cambridge and colleagues [19] in
patients with RA and the other by Seror and colleagues [20]
in patients with Sjögren's syndrome. These results support a
constitutive expression of BAFF by stromal cells in lymphoid
organs [6,34]. The results also indicate that there is no imme-
diate negative regulation of BAFF secretion when the main
BAFF consumers (the B cells) are absent or significantly
reduced in numbers, as has been demonstrated in the murine
setting [6]. A recent report, however, suggests a delayed reg-
ulation of BAFF mRNA transcription in rheumatic patients after
rituximab treatment [35].
Regarding APRIL, this is the first study to measure potential
changes in concentration upon rituximab-induced B-cell
depletion. Different patterns were observed in the two patient
cohorts: a significant decrease occurred after B-cell depletion
in the patients with SLE, whereas in the patients with RA we
observed a scattered pattern. Thus, differential effects were
seen in changes of BAFF and APRIL upon treatment. This has
also been reported after high-dose corticosteroid treatment of
patients with SLE: levels of APRIL remained the same before
and after treatment, whereas BAFF levels decreased [27]. Our
data warrant further extended and mechanistic studies to elu-
cidate the regulation of BAFF and APRIL, including their
receptor expression due to effects of different treatments in
the different rheumatic diseases.
One concern with the increased availability of BAFF, even if
only temporary, is the risk of an increased output of autoreac-
tive B cells. Such an effect has been demonstrated in BAFF
transgenic mice, especially under lymphopenic conditions
[2,34,36]. Autoreactive B cells are normally eliminated by B-
cell-receptor-induced apoptosis during negative selection in
the periphery. However, this could be inhibited by the
increased availability of BAFF, which by binding to the BAFF-
R induces upregulation of anti-apoptotic proteins [4,34].
Another concern is the association of increased BAFF and
APRIL levels with different forms of (non-Hodgkin) lymphomas
[9,11,37]. In parallel, data exist on increased risk of lympho-
mas in patients with SLE and RA [38]. Also, plasmablast sur-
vival is likely to be enhanced with high levels of BAFF [24].
Moreover, BAFF induces Mcl-1 expression in plasma cells,
which is necessary for their survival in the bone marrow [3,25].
Thus, also plasmablasts and plasma cells could be affected by
the increased levels of BAFF after rituximab treatment, which
could contribute to re-manifest the disease although that
occurs long after B-cell repopulation in most patients.
Whether and how APRIL affects plasma cells and their migra-
tion to the bone marrow remain to be elucidated. APRIL is
believed to be involved by binding syndecan-1 (CD138) and
in triggering TACI- and/or BCMA-mediated survival signals
[5].
Not only B cells are affected by BAFF and APRIL. There are
studies showing effects on T cells also [39] (reviewed by Sch-
neider [4]). T-cell survival can be enhanced when the BAFF-R
is upregulated upon activation, Bcl-2 is induced, and apopto-
sis is prevented. BAFF can also co-stimulate T cells. Moreover,
human T cells stimulated with BAFF secrete IFN-γ and IL-2
and upregulate CD25 [4]. Indeed, we found an increase of
CD25 on both CD4+ and CD8+ T cells in our cohort of rituxi-
mab-treated SLE patients [18]. Our data support the sugges-
tion by Cambridge and colleagues [19] that rituximab-treated
patients may benefit from complementary anti-BAFF therapy to
temporarily remove excess BAFF.
Conclusion
In this study, we have demonstrated that BAFF levels
increased significantly after B-cell depletion and decreased
upon B-cell repopulation in our SLE cohort (n = 10) treated
with rituximab. The similar changes observed in RA patients (n
= 9) treated with a different rituximab protocol suggest that
this pattern is likely a consequence of the B-cell depletion per
se. Patients with SLE had normal levels of APRIL at baseline,
and during depletion there was a significant decrease. The
contrasting results from our RA patient cohort, whose APRIL
levels were 10-fold higher than normal and did not change dur-
ing depletion, suggest that APRIL can be differently regulated
in RA patients. Our patient groups are small, so these findings
need to be confirmed, but given that the cohorts had defined
inclusion criteria they represent homogenous subgroups
within their respective diseases. In summary, our data suggest
that BAFF and APRIL are differentially regulated in SLE and
RA and, in addition, heterogeneously affected by rituximab
treatment.
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